ASH News Daily 2012 - Monday, December 10, 2012 - (Page B-14)

Page B–14 ® ASH NewS DAily Monday, December 10, 2012 career-developmenT awardS Long-Standing Scholar Program Supports Future of Hematology F or over two decades, ASH has supported more than 200 fellows and junior faculty in both basic and clinical/translational research by providing partial salary or other support during the critical period required for completion of training and achievement of status as an independent investigator. The following class of ASH Scholars began their awards on July 1, 2012. To find out more about the ASH Scholar Awards program, please visit www. hematology.org/awards. Jing Yang, PhD Dr. Yang is an assistant professor of medicine in the Department of Lymphoma and Myeloma at the University of Texas, MD Anderson Cancer Center, where she completed her postdoctoral training. Dr. Yang received her PhD from Xiangya Medical College, Central South University, China. As a postdoctoral student, she explored the ability of monoclonal antibodies against human ß2-microglobulin to induce apoptosis in myeloma and elucidate the underlying mechanism. Dr. Yang received a Scholar Award in 2008 for translational research of antibody therapy for myeloma. Since her promotion to assistant professor, her laboratory’s primary research focus is on studying the interaction of myeloma cells with bone marrow microenvironment, investigating the pathogenesis of myJing Yang, PhD eloma-associated bone destruction, lesions in myeloma, and she sinand developing potential therapeu- cerely thanks ASH for its continued tic approaches for this disease. Her support. laboratory recently made a novel discovery that p38 MAPK activ- Rafael Bejar MD, PhD ity in myeloma cells contributes to Dr. Bejar has already had a widemyeloma-induced osteolytic bone ranging scientific career that began destruction. Ongoing studies are di- with a bachelor’s degree in physrected toward a better understand- ics at the Massachusetts Institute of ing of myeloma cell Technology and was p38 MAPK activity in followed by a medical bones, in osteoclast acdegree from the Unitivation, and osteoblast versity of California, inhibition. These studSan Diego (UCSD), ies put emphasis on where he also earned translating the results a PhD in neurosciinto providing better ences, studying motherapeutic targets for lecular mechanisms of myeloma bone disease. learning and memory Dr. Jing Yang has rein transgenic mice. ceived a Scholar Award After an internship to study the role of tumor cell p38 MAPK ac»» SCHOLARS Page B-20 tivity in osteolytic bone Rafael Bejar MD, PhD Now Enrolling Randomized Phase II Study of Bortezomib/Dexamethasone With or Without Elotuzumab in Relapsed/Refractory Multiple Myeloma Subjects Sponsored by Bristol-Myers Squibb and Abbott The main objectives of the study are progression-free survival, response rate, duration of response, and safety of the addition of elotuzumab to bortezomib/dexamethasone. To learn more about this study please go to www.Clinicaltrials.gov/show/NCT01478048 Scan this QR code with your smartphone to go directly to the site.  http://www.hematology.org/awards http://www.hematology.org/awards

Table of Contents for the Digital Edition of ASH News Daily 2012 - Monday, December 10, 2012

ASH News Daily 2012 - Monday, December 10, 2012

https://www.nxtbookmedia.com